HNO donors represent a promising therapeutic approach for acutely decompensated heart failure due to their unique positive inotropic and lusitropic effects mediated via redox switches.
No takes yet. Share an insight, caveat, or question.
HNO donors may merit targeted development for acute decompensated HF; leaves open confirmation of clinical benefit and safety in prospective trials.
Tocchetti et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: